What drove BMY's EPS growth in Q2 2024?

Bristol-Myers Squibb's (BMY) EPS growth in Q2 2024 was primarily driven by strong product sales and strategic cost savings, despite a net loss due to acquisition charges: 1. **Product Sales Performance**: Key brands like Eliquis, Opdivo, and Reblozyl showed robust performance, contributing to the overall revenue growth. New product launches and market expansions also contributed to the growth in sales. 2. **Strategic Savings Initiatives**: The company is executing strategic productivity initiatives projected to save approximately $1.5 billion by the end of 2025, with the majority of these savings being reinvested in innovation and growth. This focus on efficiency and cost management likely had a positive impact on EPS growth. Overall, BMY's EPS growth in Q2 2024 was driven by strong sales of key products and strategic cost-saving measures, despite the impact of acquisition charges.